Iannone Robert sells $19.2M of JAZZIannone Robert 内部减持 爵士制药 (JAZZ) $19.2M
English
Executive Vice President, Global Head of R&D & CMO Iannone Robert sold 76,921 common shares of Jazz Pharmaceuticals (JAZZ) at $249.70 per share on August 27, 2026, for a total transaction value of approximately $19,207,098. The open-market sale was filed with the U.S. Securities and Exchange Commission (SEC) via a Form 4 on August 31, 2026. The sale value represents 0.122% of Jazz’s then-current $15.7 billion market capitalization.
As a senior executive overseeing the company’s core R&D and commercial operations, Robert’s sale is not a routine small-scale holding adjustment. Compared to typical minor insider trades, the size of the transaction and its relative share of the company’s market cap make this a notable ownership signal, rather than a routine administrative change to personal holdings.
Consistent with contemporaneous SEC filings, Robert submitted multiple additional non-exempt open-market sales on August 31, 2026, which collectively totaled exactly 76,921 shares — matching the size of the August 27 transaction. These filings included 10 separate trades ranging from 300 shares to 19,639 shares, with aggregate proceeds of roughly $19.5 million, in addition to several exempt M-type trades, showing a concentrated pattern of recent personal holding adjustments. Additionally, the transaction coincided with two key company announcements: the August 26 FDA approval of Ziihera for expanded HER2-positive gastric cancer use, and the August 27 pricing of a $1.1 billion exchangeable senior note offering and concurrent share repurchase program.
Follow-up markers
This Form 4 sale data alone does not confirm the transaction’s underlying personal motivation, whether it was executed under a pre-arranged 10b5-1 plan, or reflect a broader judgment of the company’s long-term value. Market participants should monitor subsequent insider ownership filings for additional changes, as well as Jazz’s upcoming third-quarter 2026 earnings report scheduled for November 4, 2026.
简体中文
执行副总裁、全球研发主管兼首席营销官Iannone Robert于2026年8月27日以每股249.70美元的价格出售76,921股Jazz Pharmaceuticals（JAZZ）普通股，交易总价值约19,207,098美元，该笔公开市场销售于2026年8月31日通过Form 4文件提交至美国证券交易委员会（SEC）。此次减持金额占JAZZ彼时157亿美元总市值的0.122%。
作为负责公司核心研发与商业化业务的高管，Iannone Robert的此次减持并非小额例行持股调整。相较于普通内部人的小额交易，该笔交易的规模及占公司市值的比例，使其成为值得关注的持仓变动信号，而非日常事务性的持股调整。
结合同期SEC备案信息，Iannone Robert在2026年8月31日同步提交了多笔额外非豁免公开市场销售交易，合计恰好76,921股，与8月27日的交易规模完全一致。这些备案包括10笔单独交易，单笔规模从300股到19,639股不等，总成交额约1950万美元，此外还有多笔免税交易，进一步显示其近期对个人持股的集中调整。此外，本次交易发生在公司近期两项重要动作之后：8月26日JAZZ刚获得FDA批准Ziihera用于HER2阳性胃癌的扩展适应症，8月27日公司同步完成了11亿美元可交换票据发行与股票回购计划。
后续关注
本次Form 4销售数据仅披露了交易的时间、规模与成交价格，无法证明该交易的个人动机、是否基于预先安排的10b5-1计划执行，也不代表对公司长期价值的整体判断。市场参与者可关注后续的内部人持股变动备案，以及Jazz Pharmaceuticals计划于2026年11月4日发布的2026年第三季度财报。
This ownership brief was prepared only from the linked SEC Form 4 and structured transaction fields. It distinguishes a completed Form 4 trade from a Form 144 planned-sale notice and does not infer a view from unrelated holdings, ratings, or market data. It is for informational purposes only and does not constitute investment advice.这篇持仓快讯仅依据页面链接的 SEC Form 4 及其结构化交易字段整理；明确区分已经成交的 Form 4 交易与 Form 144 拟出售计划，不引用无关持仓、评级或行情来推断内部人观点。内容仅供参考，不构成投资建议。